BIM
ABUS icon

BlackRock Investment Management’s Arbutus Biopharma ABUS Stock Holding History

BlackRock Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16
Closed – – 4116
2015
Q1 		$0 Buy
+16
New +$328 ﹤0.01% 4060
2014
Q4 		– Sell
-24,000
Closed -$507K – 4121
2014
Q3 		$507K Hold
24,000
– – ﹤0.01% 2964
2014
Q2 		$313K Buy
+24,000
New +$340K ﹤0.01% 3185

Other funds holding ABUS

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

BlackRock Investment Management's ABUS Position: Q2 2015 in Review

BlackRock Investment Management sold out of Arbutus Biopharma (ABUS) in Q2 2015, closing a stake of 16 shares.

BlackRock Investment Management first reported a position in ABUS in Q2 2014 and held it in 3 quarters. The position peaked at $507K in Q3 2014. 63 funds tracked by Wall St. Rank hold ABUS as of Q2 2015.

  • BlackRock Investment Management reported no remaining Arbutus Biopharma position as of Q2 2015 after selling out during the quarter.
  • BlackRock Investment Management sold 16 Arbutus Biopharma shares in Q2 2015.
  • BlackRock Investment Management first reported a position in Arbutus Biopharma in Q2 2014 and held it in 3 quarters.
  • BlackRock Investment Management's Arbutus Biopharma position peaked at $507K in Q3 2014.
  • 63 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2015.

Based on BlackRock Investment Management's 13F filing for Q2 2015, filed 7 Aug 2015.